Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056778 | 0.87 | RECQL (0.56) | ALDH1A1TDP1TSHRRECQLMAPT | |
| SCHEMBL11341567 | 0.86 | RECQL (0.58) | ALDH1A1TDP1TSHRRECQLHTT | |
| SCHEMBL3011511 | 0.84 | KDM4E (0.59) | ALDH1A1TDP1TSHRRECQLMAPT | |
| SCHEMBL4014549 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TDP1TSHRMAPTCYP3A4 | |
| SCHEMBL25496436 | 0.83 | RECQL (0.52) | ALDH1A1TDP1TSHRRECQLMAPT | |
| SCHEMBL10747235 | 0.83 | RECQL (0.52) | ALDH1A1TDP1TSHRRECQLHTT | |
| SCHEMBL28858610 | 0.83 | HTT (0.65) | ALDH1A1TDP1TSHRRECQLMAPT | |
| SCHEMBL28216207 | 0.83 | ACHE (0.56) | ALDH1A1TDP1TSHRACHEMAPT | |
| SCHEMBL8571768 | 0.82 | HSD17B10 (0.53) | TDP1RECQLMAPTHTTPKM | |
| SCHEMBL5505279 | 0.82 | CYP4F2 (0.54) | ALDH1A1TDP1RECQLMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-10-05 | — | — | US | disclosed |
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| CN-1264838-C | Indole derivatives for treating central nervous system disease | LUNDBECK & CO AS H (DK) | 2006-07-19 | — | — | CN | disclosed |
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA PHARMA S.A. (FR) | 2005-10-27 | — | — | US | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6897210-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED | 2004-12-02 | — | — | US | disclosed |
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| CN-1231662-A | Quinazoline derivatives and pharmaceutical compositions containing them | ZENNECA LTD (GB) | 1999-10-13 | — | — | CN | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | RNGTT, POLRMT, DNTT | ALDH1A1 1261/4885TDP1 123/4885TSHR 2392/4885 |
| US-20040242574-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, FLT1, NR5A1 | ALDH1A1 2260/4885TDP1 2133/4885TSHR 397/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | ALDH1A1 2757/4885TDP1 3987/4885TSHR 182/4885 |
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | ALDH1A1 2164/4885TDP1 1351/4885TSHR 2451/4885 |
| US-20050239777-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | NR5A1, NR5A2, CNKSR1 | ALDH1A1 2757/4885TDP1 3987/4885TSHR 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.